Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.
Drugs that inhibit insulin-like growth factor 1 (IGFI) receptor IGFIR were encouraging in early trials, but predictive biomarkers were lacking and the drugs provided insufficient benefit in unselected patients. In this study, we used genetic screening and downstream validation to identify the WNT pa...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for Cancer Research Inc.
2014
|
| _version_ | 1797060797220782080 |
|---|---|
| author | Gao, S Bajrami, I Verrill, C Kigozi, A Ouaret, D Aleksic, T Asher, R Han, C Allen, P Bailey, D Feller, S Kashima, T Athanasou, N Blay, J Schmitz, S Machiels, J Upile, N Jones, T Thalmann, G Ashraf, S Wilding, J Bodmer, W Middleton, MR Ashworth, A Lord, C |
| author_facet | Gao, S Bajrami, I Verrill, C Kigozi, A Ouaret, D Aleksic, T Asher, R Han, C Allen, P Bailey, D Feller, S Kashima, T Athanasou, N Blay, J Schmitz, S Machiels, J Upile, N Jones, T Thalmann, G Ashraf, S Wilding, J Bodmer, W Middleton, MR Ashworth, A Lord, C |
| author_sort | Gao, S |
| collection | OXFORD |
| description | Drugs that inhibit insulin-like growth factor 1 (IGFI) receptor IGFIR were encouraging in early trials, but predictive biomarkers were lacking and the drugs provided insufficient benefit in unselected patients. In this study, we used genetic screening and downstream validation to identify the WNT pathway element DVL3 as a mediator of resistance to IGFIR inhibition. Sensitivity to IGFIR inhibition was enhanced specifically in vitro and in vivo by genetic or pharmacologic blockade of DVL3. In breast and prostate cancer cells, sensitization tracked with enhanced MEK-ERK activation and relied upon MEK activity and DVL3 expression. Mechanistic investigations showed that DVL3 is present in an adaptor complex that links IGFIR to RAS, which includes Shc, growth factor receptor-bound-2 (Grb2), son-of-sevenless (SOS), and the tumor suppressor DAB2. Dual DVL and DAB2 blockade synergized in activating ERKs and sensitizing cells to IGFIR inhibition, suggesting a nonredundant role for DVL3 in the Shc-Grb2-SOS complex. Clinically, tumors that responded to IGFIR inhibition contained relatively lower levels of DVL3 protein than resistant tumors, and DVL3 levels in tumors correlated inversely with progression-free survival in patients treated with IGFIR antibodies. Because IGFIR does not contain activating mutations analogous to EGFR variants associated with response to EGFR inhibitors, we suggest that IGF signaling achieves an equivalent integration at the postreceptor level through adaptor protein complexes, influencing cellular dependence on the IGF axis and identifying a patient population with potential to benefit from IGFIR inhibition. |
| first_indexed | 2024-03-06T20:21:59Z |
| format | Journal article |
| id | oxford-uuid:2e1eca82-a18c-4099-bebe-70a93fffca3a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:21:59Z |
| publishDate | 2014 |
| publisher | American Association for Cancer Research Inc. |
| record_format | dspace |
| spelling | oxford-uuid:2e1eca82-a18c-4099-bebe-70a93fffca3a2022-03-26T12:47:06ZDsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2e1eca82-a18c-4099-bebe-70a93fffca3aEnglishSymplectic Elements at OxfordAmerican Association for Cancer Research Inc.2014Gao, SBajrami, IVerrill, CKigozi, AOuaret, DAleksic, TAsher, RHan, CAllen, PBailey, DFeller, SKashima, TAthanasou, NBlay, JSchmitz, SMachiels, JUpile, NJones, TThalmann, GAshraf, SWilding, JBodmer, WMiddleton, MRAshworth, ALord, CDrugs that inhibit insulin-like growth factor 1 (IGFI) receptor IGFIR were encouraging in early trials, but predictive biomarkers were lacking and the drugs provided insufficient benefit in unselected patients. In this study, we used genetic screening and downstream validation to identify the WNT pathway element DVL3 as a mediator of resistance to IGFIR inhibition. Sensitivity to IGFIR inhibition was enhanced specifically in vitro and in vivo by genetic or pharmacologic blockade of DVL3. In breast and prostate cancer cells, sensitization tracked with enhanced MEK-ERK activation and relied upon MEK activity and DVL3 expression. Mechanistic investigations showed that DVL3 is present in an adaptor complex that links IGFIR to RAS, which includes Shc, growth factor receptor-bound-2 (Grb2), son-of-sevenless (SOS), and the tumor suppressor DAB2. Dual DVL and DAB2 blockade synergized in activating ERKs and sensitizing cells to IGFIR inhibition, suggesting a nonredundant role for DVL3 in the Shc-Grb2-SOS complex. Clinically, tumors that responded to IGFIR inhibition contained relatively lower levels of DVL3 protein than resistant tumors, and DVL3 levels in tumors correlated inversely with progression-free survival in patients treated with IGFIR antibodies. Because IGFIR does not contain activating mutations analogous to EGFR variants associated with response to EGFR inhibitors, we suggest that IGF signaling achieves an equivalent integration at the postreceptor level through adaptor protein complexes, influencing cellular dependence on the IGF axis and identifying a patient population with potential to benefit from IGFIR inhibition. |
| spellingShingle | Gao, S Bajrami, I Verrill, C Kigozi, A Ouaret, D Aleksic, T Asher, R Han, C Allen, P Bailey, D Feller, S Kashima, T Athanasou, N Blay, J Schmitz, S Machiels, J Upile, N Jones, T Thalmann, G Ashraf, S Wilding, J Bodmer, W Middleton, MR Ashworth, A Lord, C Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. |
| title | Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. |
| title_full | Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. |
| title_fullStr | Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. |
| title_full_unstemmed | Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. |
| title_short | Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. |
| title_sort | dsh homolog dvl3 mediates resistance to igfir inhibition by regulating igf ras signaling |
| work_keys_str_mv | AT gaos dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT bajramii dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT verrillc dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT kigozia dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT ouaretd dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT aleksict dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT asherr dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT hanc dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT allenp dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT baileyd dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT fellers dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT kashimat dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT athanasoun dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT blayj dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT schmitzs dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT machielsj dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT upilen dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT jonest dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT thalmanng dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT ashrafs dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT wildingj dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT bodmerw dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT middletonmr dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT ashwortha dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling AT lordc dshhomologdvl3mediatesresistancetoigfirinhibitionbyregulatingigfrassignaling |